|
|
Exchange: |
N/A |
Security
Type: |
N/A |
Shares
Out: |
113,340,000 |
Market
Cap: |
128.07(M) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$0.6758 - $2.77 |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Karyopharm Therapeutics is a pharmaceutical company focused on the discovery, development, and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. Co.'s main asset, XPOVIO® (selinexor), a Selective Inhibitors of Nuclear Export compound, is indicated for use in adult patients with multiple myeloma who have received at least one prior therapy; adult patients with relapsed or refractory multiple myeloma who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors; and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
41,140 |
41,140 |
Total Buy Value |
$0 |
$0 |
$49,985 |
$49,985 |
Total People Bought |
0 |
0 |
1 |
1 |
Total Buy Transactions |
0 |
0 |
1 |
1 |
Total Shares Sold |
255,827 |
267,169 |
308,707 |
975,987 |
Total Sell Value |
$306,355 |
$315,908 |
$380,503 |
$4,268,294 |
Total People Sold |
6 |
6 |
6 |
8 |
Total Sell Transactions |
19 |
22 |
33 |
58 |
End Date |
2024-02-04 |
2023-11-03 |
2023-05-05 |
2022-05-05 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Shacham Sharon |
President & CSO |
|
2021-02-11 |
4 |
S |
$15.52 |
$103,077 |
D/D |
(6,642) |
764,147 |
|
33% |
|
Mason Michael |
SVP, CFO & Treasurer |
|
2021-02-11 |
4 |
S |
$15.52 |
$44,354 |
D/D |
(2,858) |
5,292 |
|
33% |
|
Shah Jatin |
EVP, Chief Medical Officer |
|
2021-02-11 |
4 |
S |
$15.52 |
$27,127 |
D/D |
(1,748) |
48,127 |
|
33% |
|
Mason Michael |
SVP, CFO & Treasurer |
|
2021-02-05 |
4 |
OE |
$0.00 |
$0 |
D/D |
8,150 |
8,150 |
|
- |
|
Shah Jatin |
EVP, Chief Medical Officer |
|
2021-02-05 |
4 |
OE |
$0.00 |
$0 |
D/D |
5,650 |
49,875 |
|
- |
|
Shacham Sharon |
President & CSO |
|
2021-02-05 |
4 |
OE |
$0.00 |
$0 |
I/I |
14,300 |
569,422 |
|
- |
|
Shacham Sharon |
President & CSO |
|
2021-02-05 |
4 |
OE |
$0.00 |
$0 |
D/D |
14,300 |
770,789 |
|
- |
|
Frenkel Ran |
EVP, Chief Dev. Officer |
|
2021-02-05 |
4 |
OE |
$0.00 |
$0 |
D/D |
5,650 |
41,384 |
|
- |
|
Lewis Tanya |
EVP, Chief Reg. Affairs |
|
2021-02-05 |
4 |
OE |
$0.00 |
$0 |
D/D |
5,650 |
6,189 |
|
- |
|
Kauffman Michael |
Chief Executive Officer |
|
2021-02-05 |
4 |
OE |
$0.00 |
$0 |
I/I |
14,300 |
770,789 |
|
- |
|
Kauffman Michael |
Chief Executive Officer |
|
2021-02-05 |
4 |
OE |
$0.00 |
$0 |
D/D |
14,300 |
569,422 |
|
- |
|
Mirza Mansoor Raza |
Director |
|
2020-12-18 |
4 |
AS |
$18.00 |
$90,000 |
D/D |
(5,000) |
0 |
|
-43% |
|
Mirza Mansoor Raza |
Director |
|
2020-12-18 |
4 |
OE |
$5.43 |
$27,150 |
D/D |
5,000 |
5,000 |
|
- |
|
Mirza Mansoor Raza |
Director |
|
2020-12-07 |
4 |
AS |
$16.04 |
$321,383 |
D/D |
(20,000) |
0 |
|
-41% |
|
Mirza Mansoor Raza |
Director |
|
2020-12-07 |
4 |
OE |
$5.43 |
$108,600 |
D/D |
20,000 |
20,000 |
|
- |
|
Primiano Christopher Brett |
EVP, CBO, GC & Secretary |
|
2020-12-01 |
4 |
AS |
$17.35 |
$2,402,227 |
D/D |
(137,061) |
4,523 |
|
-40% |
|
Primiano Christopher Brett |
EVP, CBO, GC & Secretary |
|
2020-12-01 |
4 |
OE |
$10.39 |
$1,428,751 |
D/D |
137,061 |
63,460 |
|
- |
|
Primiano Christopher Brett |
EVP, CBO, GC & Secretary |
|
2020-11-02 |
4 |
AS |
$14.92 |
$11,518 |
D/D |
(772) |
4,523 |
|
-13% |
|
Lewis Tanya |
EVP,Chief Reg.&Quality Officer |
|
2020-10-30 |
4 |
S |
$15.58 |
$3,521 |
D/D |
(226) |
539 |
|
17% |
|
Lewis Tanya |
EVP,Chief Reg.&Quality Officer |
|
2020-10-28 |
4 |
OE |
$0.00 |
$0 |
D/D |
765 |
765 |
|
- |
|
Primiano Christopher Brett |
EVP, CBO, GC & Secretary |
|
2020-10-13 |
4 |
AS |
$16.85 |
$661,969 |
D/D |
(39,271) |
4,649 |
|
-7% |
|
Primiano Christopher Brett |
EVP, CBO, GC & Secretary |
|
2020-10-13 |
4 |
OE |
$9.21 |
$362,537 |
D/D |
39,271 |
5,370 |
|
- |
|
Kauffman Michael |
Chief Executive Officer |
|
2020-10-12 |
4 |
AS |
$14.89 |
$111,683 |
I/I |
(7,500) |
756,489 |
|
-1% |
|
Kauffman Michael |
Chief Executive Officer |
|
2020-10-12 |
4 |
OE |
$0.03 |
$248 |
I/I |
7,500 |
763,989 |
|
- |
|
Shacham Sharon |
President & CSO |
|
2020-10-12 |
4 |
AS |
$14.89 |
$111,683 |
D/D |
(7,500) |
756,489 |
|
-1% |
|
592 Records found
|
|
Page 7 of 24 |
|
|